Patients with advanced non-small cell lung cancer and uncommon EGFR mutations lived almost twice as long without disease progression with the targeted agent afatinib (Gilotrif) versus chemotherapy ...

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...

Aims: To determine the maximum tolerated dose (MTD), safety and anti-tumor activity of afatinib combined with docetaxel in advanced cancer. Patients & methods: The MTD was determined from dose ...

Boehringer Ingelheim announced the initiation of a Phase 3 trial of afatinib for the treatment of patients with advanced (metastatic) breast cancer. This trial, called the “LUX-Breast 1 Trial ...

Afatinib (Giotrif, Boehringer Ingelheim) is an irreversible tyrosine kinase inhibitor (TKI) that blocks the epidermal growth factor receptor (EGFR) ErbB1 and other members of the ErbB family. The ErbB ...

MADRID — The oral tyrosine kinase inhibitor afatinib (Gilotrif, Boehringer Ingelheim) has shown a modest benefit in patients with recurrent and metastatic head and neck cancer in a phase 3 trial ...

Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more from afatinib than gefitinib as first-line treatment, researchers report. Patients with EGFR-activating ...

Afatinib (trade name: Giotrif) has been approved since April 2016 for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) of squamous histology who have ...

Afatinib almost doubled progression-free survival versus chemotherapy in advanced lung cancer with uncommon EGFR mutations. The treatment effect was consistent across major uncommon mutations ...